NLRP3 and cryopyrin-associated periodic syndrome: There is no apparent selective advantage demonstrated for CAPS.  Mutated cryopyrins can be found in at least 60% of patients, leading to the constitutive activation of the inflammasome and subsequent dysregulated IL-1 overproduction: excessive IL-1 signaling appears to be a constant feature in the background of CAPS, driven by gain-of-function NLRP3 mutations [35].